Cetuximab Case Study

Generally, patent biologics are in the cleft of expiration and there are a rise in the demand for biosimilar. Our company will start to develop biosimilar for Cetuximab (Erbitux), which is an epidermal growth factor receptor (EGFR) inhibitor. Eli Lilly produces the drug in the U.S and Canada market whereas Merm KGaA produced Cetuximab for territory outside the USA and Canada. We want to pursue a biosimilar for Cetuximab to build a brand image and find finance to move to our main focus, which is biosimilar for Blinatumomab. Blinatumomab (Blincyto) is a bifunctional antibody that used to treat Philadelphia chromosome-negative refractory acute lymphoblastic leukemia. Blinatumomab approved in December 2014 by the US Food and Drug Administration under the accelerated approval program.
Our company want to major in follow on biologics of bifunctional antibodies. The bifunctional antibodies market is still infancy and certainly first companies enter to this flied will have a competitive advantage over other biopharma companies. Therefor, we want to be one of the first companies starting in the field of follow on bifunctional antibodies. Nonetheless, many big pharma companies attracted to biosimilar market since they are in patent cleft thus they are trying to collaborate with other companies to produce biosimilar. For example, Pfizer established a collaborative with Biocon to produce biosimilar for insulin. As a new company, Innovace want to collaborate with biopharma company in China to magnify our business and brand name so then we can stand in the biosimilar